A Phase1 Study of VIB9600
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Safety Issues
In brief
Overall design: Single-center, randomized, blinded, placebo-controlled single- and multiple-ascending dose study in healthy adult subjects.
Key facts
- Study ID
- NCT03621605
- Run by
- Amgen
- People needed
- 24
- Starts
- 2018-08-14
- Expected to finish
- 2019-04-08
- Last updated by the study team
- 2024-12-13
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- CTI Clinical Trial & Consulting Clinical Research Center — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.